Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.34), $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $0 versus the consensus estimate of $191.77 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Sionna Therapeutics (SION) Reiterated at Market Outperform by Citizens: Readouts Upcoming